Skip to main content

Table 3 Subgroup analysis: baseline demographics of patients with idiopathic pulmonary fibrosis before and after propensity score matching – intensive care unit respiratory hospitalizations requiring mechanical ventilation

From: Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications

  Before propensity score matching After propensity score matching
No Rx (N = 751) Pirfenidone/Nintedanib (N = 94) Std. Diff No Rx (N = 94) Pirfenidone/Nintedanib (N = 94) Std. Diff
Age group
45–64 119 (15.8%) 15 (16.0%) 0.003 19 (20.2%) 15 (16.0%) − 0.111
65–74 248 (33.0%) 46 (48.9%) 0.328 5 (47.9%) 46 (48.9%) 0.021
75 +  384 (51.1%) 33 (35.1%) − 0.328 30 (31.9%) 33 (35.1%) − 0.068
Gender
Female 318 (42.3%) 26 (27.7%) − 0.312 27 (28.7%) 26 (27.7%) − 0.024
Male 433 (57.7%) 68 (72.3%) 0.312 67 (71.3%) 68 (72.3%) 0.024
Race
White 470 (62.6%) 58 (61.7%) − 0.018 61 (64.9%) 58 (61.7%) − 0.066
Black 75 (10.0%) 6 (6.4%) − 0.132 3 (3.2%) 6 (6.4%) 0.150
Hispanic 87 (11.6%) 15 (16.0%) 0.127 13 (13.8%) 15 (16.0%) 0.060
Other 119 (15.8%) 15 (16.0%) 0.003 17 (18.1%) 15 (16.0%) − 0.057
Census region
Midwest 178 (23.7%) 27 (28.7%) 0.114 30 (31.9%) 27 (28.7%) − 0.069
Northeast 113 (15.0%) 9 (9.6%) − 0.167 12 (12.8%) 9 (9.6%) − 0.101
South 402 (53.5%) 50 (53.2%) − 0.007 43 (45.7%) 50 (53.2%) 0.149
West 58 (7.7%) 8 (8.5%) 0.029 9 (9.6%) 8 (8.5%) − 0.037
Baseline comorbidities
Cardiac Arrhythmia 350 (46.6%) 30 (31.9%) − 0.303 30 (31.9%) 30 (31.9%) 0.000
Congestive Heart Failure 337 (44.9%) 28 (29.8%) − 0.315 25 (26.6%) 28 (29.8%) 0.071
Other Chronic Pulmonary Conditions 604 (80.4%) 65 (69.1%) − 0.261 70 (74.5%) 65 (69.1%) − 0.118
Depression 165 (22.0%) 22 (23.4%) 0.034 23 (24.5%) 22 (23.4%) − 0.025
Diabetes 310 (41.3%) 36 (38.3%) − 0.061 38 (40.4%) 36 (38.3%) − 0.043
Hypertension 604 (80.4%) 65 (69.1%) − 0.261 64 (68.1%) 65 (69.1%) 0.023
Pulmonary Circulation Disorder 216 (28.8%) 27 (28.7%) − 0.001 25 (26.6%) 27 (28.7%) 0.047
Renal Failure 184 (24.5%) 13 (13.8%) − 0.273 14 (14.9%) 13 (13.8%) − 0.030
Solid Tumor without Metastasis 119 (15.8%) 10 (10.6%) − 0.154 9 (9.6%) 10 (10.6%) 0.035
Valvular Disease 207 (27.6%) 19 (20.2%) − 0.173 20 (21.3%) 19 (20.2%) − 0.026
Elixhauser comorbidity index
Mean (SD) 6.3 (3.3) 4.9 (3.0) − 0.414 5.1 (3.2) 4.9 (3.0) − 0.061
Median 6.0 5.0 −  4.5 5.0 − 
Q1, Q3 4.0, 9.0 3.0, 6.0 −  3.0, 8.0 3.0, 6.0 − 
N hospitalizations in baseline
0 383 (51.0%) 61 (64.9%) 0.284 54 (57.4%) 61 (64.9%) 0.153
1 211 (28.1%) 24 (25.5%) − 0.058 25 (26.6%) 24 (25.5%) − 0.024
2 +  157 (20.9%) 9 (9.6%) − 0.319 15 (16.0%) 9 (9.6%) − 0.192
Year of hospitalization
2015 176 (23.4%) 12 (12.8%) − 0.280 10 (10.6%) 12 (12.8%) 0.066
2016 204 (27.2%) 30 (31.9%) 0.104 29 (30.9%) 30 (31.9%) 0.023
2017 200 (26.6%) 27 (28.7%) 0.047 31 (33.0%) 27 (28.7%) − 0.092
2018 171 (22.8%) 25 (26.6%) 0.089 24 (25.5%) 25 (26.6%) 0.024
Reason for admission
Diseases of respiratory system 562 (74.8%) 47 (50.0%) − 0.530 40 (42.6%) 47 (50.0%) 0.150
Diseases affecting the interstitium 144 (19.2%) 44 (46.8%) 0.615 49 (52.1%) 44 (46.8%) − 0.107
All other reasons 45 (6.0%) 3 (3.2%) − 0.134 5 (5.3%) 3 (3.2%) − 0.106
Pulmonologist visit 408 (54.3%) 80 (85.1%) 0.709 85 (90.4%) 80 (85.1%) − 0.162
Smoker 414 (55.1%) 46 (48.9%) − 0.124 52 (55.3%) 46 (48.9%) − 0.127
Steroid use 420 (55.9%) 69 (73.4%) 0.371 69 (73.4%) 69 (73.4%) 0.000
Oxygen use 484 (64.4%) 83 (88.3%) 0.433 74 (78.7%) 83 (88.3%) 0.053